CLEVELAND With the goal of developing new, more effective and personalized cancer treatments, Horizon Discovery, based in Cambridge, England, has secured from Case Western Reserve University exclusive rights to a panel of new human isogenic cell models developed by the laboratory of Zhenghe John Wang, assistant professor of genetics at the university's School of Medicine.
The license is initially for 10 years and includes up-front fees and an ongoing royalty on product sales. The genetically engineered cell lines are based on a new technology invented by Wang and his associates two years ago.
Human isogenic cell models known as cell lines and sometimes referred to as "patients-in-a-test-tube" accurately mimic disease-causing mutations, enabling researchers to better understand how cancer manifests itself in patients and to identify the effect of drug therapies and various outcomes.
"These cell lines provide unique tools for drug discovery, because they are cells that best represent human cancers. Further research based on these cells may lead to development of new cancer therapies," Wang said.
The lines will be added to Horizon Discovery's rapidly expanding library of X-MANTM (gene X- Mutant And Normal) cell models, which are used to successfully predict which patient groups will respond to currently available and future drug treatments. Research involving Horizon Discovery's proprietary rAAV GENESIS gene-editing platform seeks to enhance drug development, leading to personalized cancer therapies.
Chris Torrance, Horizon Discovery's co-founder and chief scientific officer, said that the cell lines will help researchers decipher how disease-associated genes work and "will open up new routes to develop novel targeted therapies."
"In partnering with Horizon, we gain a tremendous opportunity to bring these unique cancer cell lines to the market," said Stacy Fening, licensing associate for life sciences in
|Contact: Marv Kropko|
Case Western Reserve University